What we’re seeing with ENTA’s recent rise is that many investors have finally decoupled the company from the Mavyret royalty stream and are evaluating ENTA as a bona fide drug-discovery and drug-development outfit.
ENTA used to move up or down strongly based on ABBV’s reported Mavyret sales, but that is no longer the case, evidently.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.